Clinical trials recruiting for Radiotherapy

Phase breakdown

Drugs and treatments being studied

Where trials are recruiting (top US states)

Top cities

Self-screener

Recruiting trials

• A Clinical Trial Comparing Long-Course Versus Short-Course Radiotherapy Followed by Immunotherapy Combined With Total Neoadjuvant Therapy (TNT) to Long-Course Radiotherapy Followed by TNT in Locally Advanced Rectal Cancer
  NCT07113275 · Phase: Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• A Pilot Study Evaluating β-hydroxybutyrate Supplementation Concomitant to Short-Course Radiotherapy Followed by Immunotherapy Combined With CAPEOX Neoadjuvant Therapy in Patients With Locally Advanced Rectal Cancer
  NCT07239466 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• A Randomized Trial of Five Fraction Partial Breast Irradiation (RAPID2)
  NCT05417516 · Phase: Phase 3 · Ages: 50 Years to 120 Years · Sex: Female · 30 locations
• Adebrelimab Injection (PD-L1) Combined With Short Course Radiotherapy and Chemotherapy for Neoadjuvant Therapy of Locally Advanced Rectal Cancer
  NCT06765616 · Phase: Phase 2 · Ages: 18 Years to 85 Years · Sex: All (male and female) · 1 location
• Assessment of Adebelizumab Combined With Chemotherapy in Concurrent Radiotherapy Versus Sequential Radiotherapy as First-Line Treatment for Extensive-Stage Small Cell Lung Cancer
  NCT06768307 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Comparison of Patient Understanding and Anxiety According to the Delivery Method of Educational Videos
  NCT07550686 · Phase: Not applicable (e.g. observational or device study) · Ages: 20 Years and older · Sex: All (male and female) · 1 location
• Different-Dose SCRT Plus CAPOX, PD-1 Blockade and IL-2 in LARC
  NCT07646639 · Phase: Phase 2 · Ages: 18 Years to 70 Years · Sex: All (male and female) · 1 location
• Efficacy and Safety of Super-hyperfractionation Pulse Radiotherapy Combined With ICIs for Advanced NSCLC
  NCT05754203 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 75 Years · Sex: All (male and female) · 2 locations
• Fruquintinib Combined With Sintilimab ± Radiotherapy for Third-line Treatment of Colorectal Cancer With Liver Metastases
  NCT06356584 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Intestinal Low Dose Radiotherapy Combined With Immunotherapy in Immune-resistant Metastatic Malignant Solid Tumors
  NCT07071103 · Phase: Phase 2 · Ages: 18 Years to 80 Years · Sex: All (male and female) · 1 location
• Level I-II Axillary Irradiation in Breast Cancer With Sentinel-Node Macro-metastases
  NCT07469267 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: Female · 15 locations
• Modified Long-Course Radiotherapy Followed by Chemotherapy and PD-1 Inhibitor for MSS/pMMR High-risk Mid/Low LARC (MODIFI-RC-I)
  NCT06923345 · Phase: Phase 2 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Node-Sparing Short-Course Radiotherapy Plus Chemotherapy, Bevacizumab and PD-1 Inhibitor in Metastatic pMMR/MSS Colorectal Cancer (MODIFI-CRC)
  NCT06958419 · Phase: Phase 2, Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Node-Sparing Short-Course Radiotherapy Sequential Chemotherapy and PD-1 Inhibitor for Mid/Low pMMR/MSS Rectal Cancer (MODIFI-RC-II)
  NCT06958432 · Phase: Phase 2, Phase 3 · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Observational Study on Extreme Hypofractionation for Localized Prostate Cancer
  NCT05344235 · Phase: Not specified · Ages: No age limits stated · Sex: Male · 1 location
• Omitting CTV for Locally Advanced NSCLC Responded to Immunotherapy and Chemotherapy
  NCT06020430 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• Primary Tumor Radiotherapy Omitting CTV for Patients With Advanced NSCLC Responded to Immunotherapy and Chemotherapy
  NCT06037733 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 75 Years · Sex: All (male and female) · 1 location
• SCRT VS LCRT Followed by PD-L1 Inhibitor Plus CAPEOX as TNT in Patients With LARC
  NCT07284992 · Phase: Phase 2 · Ages: 18 Years to 80 Years · Sex: All (male and female) · 1 location
• Safety, Efficacy, and Survival Outcomes of Neoadjuvant/Induction Immunotherapy in Surgical and Radiotherapeutic Management of Non-Small Cell Lung Cancer
  NCT06926179 · Phase: Not specified · Ages: 18 Years and older · Sex: All (male and female) · 4 locations
• Serial MRI Scans During Radiation Therapy
  NCT04188535 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years and older · Sex: All (male and female) · 2 locations
• Sintilimab Plus Hypofractionated Radiotherapy for MSI-H/dMMR Rectal Cancer
  NCT04636008 · Phase: Phase 1, Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Spatially Fractionated Radiotherapy Combined With Immunotherapy for Advanced Solid Tumors
  NCT07058948 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 3 locations
• Stereotactic Re-irradiation of Local Recurrences of Prostate Cancer After Radiotherapy
  NCT06201078 · Phase: Phase 2 · Ages: 18 Years to 80 Years · Sex: Male · 1 location
• Targeted Induction Therapy for Stage III Unresectable EGFR Mutant Positive NSCLC
  NCT07742332 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• The Impact of Metastatic Directed Radiotherapy (MDRT) on Oligoprogressive Castration Resistant Prostate Cancer (CRPC)
  NCT07038304 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Male · 2 locations
• The Postoperative Radiotherapy in N1 Breast Cancer Patients
  NCT05440149 · Phase: Phase 3 · Ages: 19 Years and older · Sex: Female · 1 location
• Thoracic Radiotherapy for Patients With Metastatic (Stage IV) Non-Small Cell Lung Cancer at High Risk of Symptomatic Progression Within the Thorax
  NCT06262321 · Phase: Phase 2 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Total Neoadjuvant Therapy and Organ Preservation Versus Surgery for Rectal Cancer.
  NCT06758830 · Phase: Phase 2, Phase 3 · Ages: 18 Years and older · Sex: All (male and female) · 1 location
• Trastuzumab Rezetecan Combined With Radiotherapy Versus Trastuzumab Rezetecan in the Treatment of HER2-positive Advanced Breast Cancer With Brain Metastases
  NCT07100600 · Phase: Phase 2 · Ages: 18 Years and older · Sex: Female · 1 location
• Ultra Hypofractionnated Radiotherapy With HDR Brachytherapy Boost.
  NCT05786742 · Phase: Not applicable (e.g. observational or device study) · Ages: 18 Years to 95 Years · Sex: Male · 1 location
• mFOLFIRINOX Plus Radiotherapy to Patients With CA19-9-normal Advanced Pancreatic Cancer Refractory to Chemotherapy
  NCT06249321 · Phase: Phase 2 · Ages: 18 Years to 80 Years · Sex: All (male and female) · 1 location

Related conditions

Trials recruiting for Radiotherapy often also study these conditions. Each links to its own recruiting-trial list.

Common questions

Are these trials free to join?

Study-related care in a clinical trial is usually provided at no cost to participants, and some trials reimburse travel. Costs vary by study - the trial team will explain what is and is not covered. Confirm this directly with them.

How do I know if I am eligible for Radiotherapy trials?

Each trial lists inclusion and exclusion criteria. The screener above checks stated age and sex only. The full eligibility (your medical history, current medications, test results) is assessed by the study team. Open any trial to read its criteria, then contact the site.

Is this list complete?

No. For the full list, search ClinicalTrials.gov.